BeOne joins reshoring parade with $300M US production expansion
BeOne joins reshoring parade with $300M US production expansion.
BeiGene
NASDAQ: BGNE ~$15B MCAP
BeiGene (NASDAQ: BGNE; HKEX: 06160) is a global oncology company developing innovative, affordable therapies for cancer patients worldwide. Best known for Brukinsa (zanubrutinib), a BTK inhibitor approved for multiple B-cell malignancies. Committed $300M in 2026 to expand US manufacturing capacity.
Company Info
Recent News
Repligen’s $1.5B buy for BioLife; BeOne’s $300M US expansion
Repligen’s $1.5B buy for BioLife; BeOne’s $300M US expansion.